Best CPAP Alternatives for Sleep Apnea 2026: Evidence-Based Options by Severity

IMPORTANT MEDICAL DISCLAIMER: Sleep apnea is a serious medical condition that requires diagnosis and management by a licensed physician. This article is for educational purposes only and is not medical advice. If you suspect you have sleep apnea, you must see a doctor—untreated moderate-to-severe sleep apnea is associated with significantly elevated risk of cardiovascular disease, stroke, type 2 diabetes, and all-cause mortality. Do not discontinue CPAP therapy or forego treatment based on anything in this article. Any treatment change, including trying alternatives discussed here, must be done under physician supervision.

CPAP (continuous positive airway pressure) therapy remains the gold standard for treating obstructive sleep apnea, and for good reason: it works. When worn consistently, CPAP reduces apnea-hypopnea index (AHI) events close to zero for most patients, eliminates oxygen desaturation events, and dramatically reduces cardiovascular risk. No alternative currently matches it for efficacy across all severity levels.

But compliance is a real problem. Studies consistently show that 30-50% of CPAP users either abandon the device within the first year or use it fewer than four hours per night—the threshold below which the cardiovascular benefits diminish substantially (Weaver & Grunstein, Proceedings of the American Thoracic Society, 2008). A patient who won't use their CPAP gains none of its benefits. For this reason, alternatives aren't fringe medicine—they're a legitimate clinical conversation, particularly for patients with mild to moderate apnea who cannot tolerate positive pressure therapy.

This guide reviews the alternatives that have genuine evidence behind them, categorized by what the research actually shows and matched to appropriate severity thresholds. We've been deliberately critical of the alternatives that are popular but not evidence-based. Understanding where the evidence is strong, where it's preliminary, and where products are outright gimmicks can help you have a more productive conversation with your sleep medicine physician.

---

Understanding Sleep Apnea Severity: Why AHI Defines Your Options

Before evaluating any alternative, you need to understand where you fall on the severity spectrum. This determines which alternatives are medically appropriate and which are not.

The AHI Scale

The Apnea-Hypopnea Index (AHI) measures the average number of complete breathing cessations (apneas) and partial breathing reductions (hypopneas) per hour of sleep:

• Mild sleep apnea: AHI 5-14 events per hour
• Moderate sleep apnea: AHI 15-29 events per hour
• Severe sleep apnea: AHI 30+ events per hour

What Each AHI Level Means Clinically

An AHI of 5-14 with no symptoms or cardiovascular risk factors may require minimal intervention. An AHI of 5-14 with daytime sleepiness, hypertension, or cardiovascular disease typically warrants treatment. At AHI 15+, treatment is almost universally recommended—the cardiovascular and neurocognitive consequences of untreated moderate sleep apnea are well-documented and accumulate over time.

The Sleep Heart Health Study (SHHS), one of the largest prospective cohort studies in sleep medicine (Punjabi et al., PLOS Medicine, 2009), followed over 6,000 adults and found that moderate-to-severe sleep apnea was independently associated with a 46% increased risk of cardiovascular mortality, even after controlling for obesity, hypertension, and other confounders. Oxygen desaturation events—when blood oxygen drops below 90%—are the proximate cause of much of this cardiovascular damage, activating sympathetic nervous system surges, promoting oxidative stress, and triggering systemic inflammation.

The Role of Oxygen Desaturation

AHI alone doesn't capture the full clinical picture. Some patients have a relatively modest AHI but deep and prolonged oxygen desaturation events; others have frequent but shallow events with minimal desaturation. Your sleep study should include both AHI and an oxygen desaturation index (ODI) or nadir SpO2—these together determine treatment urgency more accurately than AHI alone.

Who Should NOT Skip CPAP

• AHI above 30 (severe sleep apnea) — evidence for alternative efficacy is substantially weaker
• Any severity with significant nocturnal oxygen desaturation (nadir SpO2 below 88%)
• History of cardiovascular disease, heart failure, or stroke
• Severe daytime sleepiness (Epworth Sleepiness Scale > 15)
• Commercial drivers or anyone in safety-critical occupations
• Complex or central sleep apnea (not obstructive)

If you fall into any of these categories, CPAP compliance should be the priority, and alternatives should only be considered after a thorough discussion with a board-certified sleep medicine physician.

---

What to Look for in a CPAP Alternative

Evaluating sleep apnea alternatives requires a different framework than evaluating most health products. Here are the criteria that matter.

Evidence Level and Study Design

Randomized controlled trials with polysomnography (PSG) outcomes—actual sleep lab measurements, not just symptom questionnaires—are the gold standard. Many alternatives have only pilot studies, case series, or proprietary outcome data from the device manufacturer. The evidentiary standard matters enormously when you're managing a condition with cardiovascular stakes.

FDA Clearance and Regulatory Status

FDA 510(k) clearance means a device has been shown to be substantially equivalent to a legally marketed predicate device—it does not mean the device has been proven efficacious in clinical trials. FDA PMA (Premarket Approval) requires clinical data demonstrating safety and effectiveness and is the higher bar. Most oral appliances and positional therapy devices have 510(k) clearance; Inspire Medical's hypoglossal nerve stimulator has PMA approval, which required substantial clinical trial data.

AHI Reduction Targets

For an alternative to be considered therapeutically equivalent to CPAP, it should reduce AHI below 5 (normal range) or achieve at least a 50% reduction with a residual AHI under 10. Alternatives that reduce AHI from 20 to 14 may improve symptoms without eliminating the cardiovascular risk.

Compatibility with Severity

No single alternative works across all severity levels. An intervention appropriate for mild apnea may be completely inadequate for severe apnea—not because the device is bad, but because the pathophysiology is different.

---

Best CPAP Alternatives of 2026

1. Inspire Medical Systems (Hypoglossal Nerve Stimulation) — Best for Moderate-to-Severe CPAP Intolerant Patients

Inspire is not a consumer product—it's a surgically implanted neurostimulation system that requires an implantation procedure performed by a specialized surgeon and is appropriate only for specific patient profiles. We include it here because it represents the most significant advance in sleep apnea treatment for CPAP-intolerant patients with moderate to severe disease.

The system consists of a small implantable device placed in the upper chest, a sensing lead near the intercostal muscles to detect breathing patterns, and a stimulation lead that delivers mild electrical impulses to the hypoglossal nerve (which controls tongue movement). When you inhale, the system stimulates the tongue to move forward and clear the airway—the same mechanism CPAP achieves through air pressure, but driven by your own neuromuscular system.

The pivotal STAR Trial (Strollo et al., New England Journal of Medicine, 2014) showed that Inspire reduced median AHI from 29.3 to 9.0 events per hour at 12 months—a 68% reduction—in CPAP-intolerant patients with moderate-to-severe OSA. A 5-year follow-up published in Laryngoscope showed sustained outcomes, with 74% of patients maintaining AHI below 15.

Why it stands out: For CPAP-intolerant patients with moderate-to-severe OSA, Inspire offers CPAP-level efficacy without the nightly compliance burden of external devices. Patient satisfaction scores are consistently high.

What we like:

• Strong, published clinical trial data (STAR Trial, NEJM)
• FDA PMA approval (highest regulatory bar)
• Covers patients who cannot tolerate CPAP
• Long-term durability demonstrated at 5+ years
• No external device, mask, or tubing to wear nightly
• Controlled with a simple remote

What could be better:

• Requires surgery (general or local anesthesia) with associated procedural risks
• Not appropriate for BMI above 35 or certain airway anatomy patterns
• Requires absence of complete concentric collapse at the palate (assessed by drug-induced sleep endoscopy)
• Expensive; insurance coverage varies
• Not a first-line option—appropriate after documented CPAP intolerance

Best for: CPAP-intolerant patients with AHI 15-65, BMI under 35, who have completed a proper ENT/sleep surgery evaluation

---

2. Mandibular Advancement Devices (SomnoMed, ProSomnus, ResMed Narval) — Best Evidence-Based Non-Surgical Alternative

Mandibular advancement devices (MADs) are custom-fitted oral appliances that hold the lower jaw (mandible) forward during sleep, which tenses the soft tissue of the upper airway and reduces its collapsibility. They are the most evidence-based non-surgical, non-pressure CPAP alternative for mild to moderate OSA.

A 2015 Cochrane systematic review of 67 trials concluded that MADs produce significant reductions in AHI, with effects particularly strong in mild to moderate OSA. A direct comparison of MADs vs. CPAP (Tan et al., Sleep, 2002; Ferguson et al., Chest, 2006) found that CPAP produced greater AHI reduction, but MADs led to equivalent or better patient-reported outcomes in some studies—because patients actually wore them.

SomnoMed MAS is a titratable two-piece device allowing millimeter-by-millimeter jaw advancement adjustment. It's among the most prescribed custom MADs globally and has been evaluated in multiple RCTs.

ProSomnus devices use a precision-milled PMMA design with a smaller footprint than traditional bulky acrylic appliances—a significant comfort advantage that improves nightly wear time.

ResMed Narval CC uses computer-aided design to custom-fabricate an appliance based on a 3D dental impression, with a documented AHI reduction of approximately 50% in mild-moderate OSA patients in manufacturer-sponsored studies.

Why it stands out: The evidence base is the strongest of any non-surgical CPAP alternative. When fit properly by a dental sleep medicine specialist, MADs achieve meaningful AHI reduction in the majority of mild-to-moderate OSA patients.

What we like:

• Extensive RCT data supporting efficacy in mild-moderate OSA
• No electricity, mask, or air pressure required
• Travel-friendly—fits in a pocket
• High patient acceptance relative to CPAP
• Titratable designs allow optimization over time
• FDA-cleared and covered by most insurance with physician prescription

What could be better:

• Requires custom fitting by a dentist trained in sleep medicine (over-the-counter alternatives are substantially less effective)
• Can cause jaw soreness, teeth shifting, or TMJ issues with prolonged use
• Takes 2-6 weeks of titration to reach optimal position
• Less effective than CPAP for severe OSA (AHI 30+)
• Initial cost of custom devices ranges $1,500-$3,000 before insurance

Best for: Mild to moderate OSA (AHI 5-29), CPAP intolerant patients, travelers, patients with relatively mild anatomy-driven obstruction

---

3. Positional Therapy Devices (Night Shift, Zzoma Belt) — Best for Positional Sleep Apnea

Approximately 50-60% of OSA patients have "positional OSA"—their AHI is substantially higher when sleeping supine (on their back) than when sleeping on their side. For these patients, preventing supine sleep is a legitimate treatment strategy with real evidence behind it.

Night Shift is an FDA-cleared device worn around the neck that vibrates when you roll onto your back, conditioning you toward side sleeping without waking you. The vibration is mild enough not to fully arouse from sleep but strong enough to trigger positional adjustment. A 2015 randomized controlled trial (Levendowski et al., Journal of Clinical Sleep Medicine) showed that Night Shift reduced AHI by 46% overall in positional OSA patients—comparable to MAD outcomes for this subgroup.

Zzoma Belt is an FDA-cleared positional belt that physically restricts supine positioning by incorporating a foam wedge on the back. A 2019 RCT published in the Journal of Clinical Sleep Medicine (Ravesloot et al.) found Zzoma non-inferior to CPAP in patients with predominantly positional OSA on several patient-reported and polysomnographic outcomes.

Why it stands out: For the specific subgroup with true positional OSA (documented by a split-night or two-night sleep study with positional data), these devices offer a simple, low-cost intervention with meaningful clinical evidence.

What we like:

• Good RCT evidence for the positional OSA subgroup
• Night Shift: unobtrusive, comfortable, travel-friendly
• Zzoma: physically enforces positioning without needing wearable tech
• Low cost compared to oral appliances or surgery
• FDA cleared
• No learning curve or titration required

What could be better:

• Only appropriate if you've been confirmed to have positional OSA—not effective for non-positional cases
• Night Shift vibration disturbs some bed partners
• Zzoma belt can feel restrictive and is less practical for position changers
• AHI reduction is incomplete—residual events still occur even in the optimal position
• Doesn't address obstruction unrelated to position

Best for: Confirmed positional OSA patients (AHI in supine ≥2x AHI in lateral), as a standalone or adjunct therapy

---

4. EPAP Devices (Bongo Rx, Theravent) — Best Minimal Intervention for Mild OSA

Expiratory Positive Airway Pressure (EPAP) devices are small nasal inserts or adhesive patches that create resistance during exhalation, which generates a small amount of positive pressure that helps keep the airway open during the subsequent inhalation. They are significantly less powerful than CPAP but have meaningful evidence for mild to moderate OSA.

Theravent is an adhesive nasal valve patch (over-the-counter) that uses a microvalve design to create expiratory resistance. A manufacturer-sponsored, but peer-reviewed, RCT published in Sleep (Berry et al., 2011) showed significant AHI reduction in mild to moderate OSA and improved daytime sleepiness versus sham.

Bongo Rx is an FDA-cleared, reusable nasal EPAP device that fits inside the nostrils. A 2017 study in Journal of Clinical Sleep Medicine demonstrated an average AHI reduction of approximately 47% from baseline in mild-moderate OSA patients.

Why it stands out: EPAP devices are the most unobtrusive sleep apnea intervention available—tiny nasal inserts with no machinery, no air tubes, no mask. For mild OSA patients who find CPAP completely unacceptable, EPAP bridges a gap.

What we like:

• Extremely small and unobtrusive
• No electricity, no mask, no hose
• Travel-friendly (Theravent fits in a pocket)
• Published clinical evidence supporting use in mild-moderate OSA
• FDA cleared (Bongo Rx: 510(k); Theravent: OTC)
• Low cost, particularly Theravent

What could be better:

• AHI reduction is partial—rarely achieves AHI < 5 in moderate cases
• Nasal obstruction, congestion, or deviated septum can prevent use
• Requires nasal breathing—mouth breathing negates the effect
• Theravent adhesive can irritate skin with prolonged nightly use
• Not appropriate for moderate-severe OSA as standalone treatment

Best for: Mild OSA (AHI 5-14), CPAP-intolerant patients who mouth breathe less, travel or backup device, adjunct to other therapies

---

5. Mouth Taping — Adjunct Only, Not a Treatment

Mouth taping has gained significant popularity in biohacking communities. The practice involves placing a small piece of medical-grade tape (or a purpose-designed breathing strip) over the lips during sleep to encourage nasal breathing. Proponents claim it reduces snoring, improves sleep quality, and treats mild sleep apnea.

The evidence for mouth taping as a sleep apnea treatment is thin. A small 2022 study in Journal of Clinical Sleep Medicine (Lee et al.) found that mouth taping reduced AHI in patients with mild OSA and a high ratio of oral-to-nasal breathing—a very specific subgroup. For most OSA patients, mouth taping alone does not meaningfully reduce AHI.

Where mouth taping has more legitimate application is as an adjunct to CPAP (to prevent mouth breathing that reduces CPAP effectiveness) or alongside EPAP devices (which only work with nasal breathing). It is not a standalone sleep apnea treatment.

Important safety note: Mouth taping is contraindicated in anyone with significant nasal obstruction, severe sleep apnea, or a history of vomiting during sleep (aspiration risk). Do not tape your mouth if you have moderate-to-severe OSA without physician approval.

Why we include it: To calibrate expectations. Mouth taping is useful in specific, narrow contexts. It is not a CPAP replacement.

What we like:

• May reduce snoring in some individuals
• Legitimate adjunct for CPAP mouth leakers
• Inexpensive and widely available
• Some evidence in the specific subgroup of mild OSA with oral-route breathing

What could be better:

• Not effective as standalone OSA treatment for most patients
• Safety concerns for mouth tapers with nasal obstruction
• Popularized beyond its evidence base by social media
• Cannot reduce AHI in patients with pharyngeal or anatomical obstruction

Best for: CPAP users with mouth leak issues; mild snoring without confirmed OSA; as an adjunct only—never as a primary sleep apnea treatment

---

The Spectrum of Sleep Apnea Severity: What the Research Actually Shows

Understanding sleep apnea requires moving beyond the simple label and grasping the spectrum of severity—because the clinical consequences of a 6 AHI and a 45 AHI are radically different, even though both qualify as "sleep apnea."

How the AHI Is Measured and What It Misses

A polysomnogram (PSG)—the overnight sleep study—simultaneously records brain waves (EEG), eye movements (EOG), muscle tone (EMG), airflow, respiratory effort, blood oxygen, and heart rhythm to construct a complete picture of sleep and breathing. The AHI is derived by dividing total respiratory events by hours slept.

Home sleep apnea tests (HSATs) are less comprehensive—most only record airflow, respiratory effort, and blood oxygen, without EEG. This means they cannot stage sleep, cannot detect certain event types, and tend to underestimate AHI compared to full PSG. This matters when choosing a treatment pathway: a home test AHI of 12 might correspond to a PSG AHI of 18, which changes the severity classification and treatment recommendation.

Oxygen Desaturation Events and Cardiovascular Risk

The Sleep Heart Health Study (SHHS), which followed 6,441 community-dwelling adults over a median 8.2 years, is the foundational epidemiological evidence base for OSA cardiovascular risk. Punjabi et al. (2009) found that men with severe OSA (AHI ≥30) had a 1.46-fold increased risk of incident cardiovascular disease compared to those without OSA, independent of all traditional cardiovascular risk factors.

More specifically, the cumulative time spent with oxygen saturation below 90% (T90) was one of the strongest predictors of adverse outcomes—more predictive than AHI alone. Each nocturnal oxygen desaturation event activates the sympathetic nervous system, causes blood pressure spikes (sometimes to hypertensive levels), and generates reactive oxygen species that damage endothelium. Repeated thousands of times per year in untreated severe OSA, these events produce measurable cardiovascular harm.

Who Is a Legitimate Candidate for CPAP Alternatives

The clinical consensus, reflected in guidelines from the American Academy of Sleep Medicine (AASM) and the European Respiratory Society (ERS), is that CPAP alternatives are most appropriate for:

1. Mild OSA (AHI 5-14) with minimal symptoms and no significant cardiovascular risk factors—lifestyle interventions (weight loss, positional therapy) and/or oral appliances are reasonable first-line options
2. Mild-to-moderate OSA (AHI 5-29) in patients who are intolerant of CPAP after adequate accommodation and pressure optimization attempts
3. Moderate OSA (AHI 15-29) where oral appliance therapy achieves documented AHI normalization (confirmed by repeat PSG or ambulatory monitoring with the device in place)
4. Positional OSA where supine AHI significantly exceeds non-supine AHI and positional devices achieve documented normalization

For these groups, alternatives are not compromises—they are legitimate, evidence-supported treatment options that may produce better real-world outcomes than a CPAP machine that never gets used.

If you're concerned about your sleep health more broadly, the sleep and longevity guide covers how sleep quality connects to healthspan and aging. For tracking your treatment response objectively, a wearable from our best sleep trackers guide can give you nightly data on oxygen saturation and heart rate variability as proxy metrics—though they should not replace a repeat sleep study for formal outcome assessment. Understanding HRV context can also be valuable for assessing autonomic impact; see our good HRV score by age guide.

---

FAQ

Can I treat sleep apnea without a CPAP?

It depends on your AHI severity and the underlying anatomy driving your obstruction. For mild sleep apnea (AHI 5-14), several alternatives have genuine clinical evidence: oral appliances, positional therapy, and EPAP devices can achieve meaningful AHI reduction. For moderate sleep apnea (AHI 15-29), alternatives require careful monitoring to confirm they're achieving adequate control—a follow-up sleep study with the alternative device in place is essential. For severe sleep apnea (AHI 30+), alternatives are rarely adequate as standalone treatment. Always make this decision with your sleep physician.

Are mandibular advancement devices as good as CPAP?

For mild to moderate OSA, MADs often produce equivalent patient-reported outcomes to CPAP—not because they work as well in a lab, but because patients actually wear them. Head-to-head RCTs consistently show CPAP achieves greater AHI reduction, but studies that measure real-world outcomes (including compliance) often find similar daytime sleepiness and quality-of-life improvement. The key is getting a custom-fitted device from a dentist trained in dental sleep medicine and confirming with follow-up PSG that your AHI is adequately controlled.

Is the Inspire implant worth it?

For the right patient—CPAP-intolerant, AHI 15-65, BMI under 35, confirmed absence of complete concentric collapse at the palate—Inspire has strong clinical evidence and high patient satisfaction. The STAR Trial data published in the New England Journal of Medicine showed sustained results at 5 years. The trade-off is that it's a surgical procedure with the associated risks and recovery. For patients who meet the criteria and have exhausted non-surgical options, it's the strongest alternative available. Discuss candidacy with a sleep medicine physician and ENT surgeon who specialize in hypoglossal nerve stimulation.

Does weight loss cure sleep apnea?

Weight loss can substantially reduce OSA severity for patients where obesity is the primary driver of airway obstruction. A landmark trial (Foster et al., New England Journal of Medicine, 2012) in obese adults with type 2 diabetes and OSA found that intensive lifestyle intervention producing significant weight loss nearly doubled the rate of OSA remission versus diabetes support and education alone. However, OSA rarely fully resolves even with significant weight loss, and many lean individuals have OSA due to anatomy rather than adiposity. Weight loss is an excellent adjunct strategy but should not be relied upon as sole treatment while awaiting results.

---

Affiliate Disclosure: Better Vitals may earn a commission when you purchase through our links. We only recommend products our team has personally tested and validated.

Last updated: March 2026. This article is reviewed by our editorial team and updated when significant new evidence or products emerge. It is not a substitute for professional medical advice.